Mirum Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Mirum Pharmaceuticals, Inc. (MIRM) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 19.12 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 22.19M shares, a 2.38% decline year-over-year.
- Mirum Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 11.84M shares, a 45.88% decline year-over-year.
- Mirum Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 22.73M shares, a 0.85% increase year-over-year.
- Mirum Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 21.89M shares.
- Mirum Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 20.71M shares, a 4.54% decline from fiscal 2024.
- Mirum Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 21.69M shares, a 3.81% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 20.90M shares, a 132.66% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 8.98M shares, a 26.75% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 19.12M shares 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | 22.19M shares 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | 20.71M shares 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | 11.84M shares 10-Q · filed 2025-11-04 | 21.20M shares 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 22.47M shares 10-Q · filed 2026-08-05 | ||||
| 2025-03-31 | 22.73M shares 10-Q · filed 2026-05-06 | ||||
| 2024-12-31 | 21.69M shares 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | 21.89M shares 10-Q · filed 2025-11-04 | 21.89M shares 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | 22.17M shares 10-Q · filed 2025-08-06 | ||||
| 2024-03-31 | 22.54M shares 10-Q · filed 2025-05-07 | ||||
| 2023-12-31 | 20.90M shares 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | 20.83M shares 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | 20.63M shares 10-Q · filed 2024-08-07 | ||||
| 2023-03-31 | 10.67M shares 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | 8.98M shares 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | 32.49K shares 10-Q · filed 2022-11-09 | 9.18M shares 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | 9.18M shares 10-Q · filed 2023-08-07 | ||||
| 2022-03-31 | 8.74M shares 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | 7.09M shares 10-K · filed 2024-03-15 | 7.09M shares 10-K · filed 2022-03-09 | |||
| 2021-09-30 | 7.35M shares 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | 7.14M shares 10-Q · filed 2021-08-05 | ||||
| 2021-03-31 | 6.75M shares 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | 5.90M shares 10-K · filed 2022-03-09 | ||||
| 2020-09-30 | 5.35M shares 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | 5.25M shares 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | 4.79M shares 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | 3.76M shares 10-K · filed 2021-03-09 | ||||
| 2019-09-30 | 3.63M shares 10-Q · filed 2019-11-06 | ||||
| 2018-12-31 | 550.78K shares 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |